Aprea Therapeutics Q4 2025 Earnings Report

Aprea Therapeutics EPS Results

• Actual EPS: -$0.32
• Consensus EPS: -$0.38
• Beat/Miss: Beat by +$0.06
• One Year Ago EPS: N/A

Aprea Therapeutics Revenue Results

• Actual Revenue: $0.00 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Aprea Therapeutics Announcement Details

• Quarter: Q4 2025
• Date: 3/16/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Aprea Therapeutics (NASDAQ:APRE) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS. In addition to its lead program, Aprea maintains a pipeline of early‐stage candidates and explores combination regimens intended to enhance response rates and overcome resistance mechanisms associated with TP53 dysfunction.

Aprea conducts global clinical development activities, collaborating with academic centers and biopharmaceutical partners in North America and Europe. These partnerships support Aprea’s efforts to accelerate trial enrollment, broaden access to investigational therapies and facilitate regulatory interactions across multiple jurisdictions.

Founded in 2013 and headquartered in San Francisco, California, Aprea is led by a management team with extensive experience in oncology drug development. The company’s scientific leadership combines expertise in molecular biology, translational research and clinical operations to advance its precision oncology approach for patients with high‐unmet‐need cancers.